Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	167.5	-	-
Gross Profit	167.5	-	-
Selling, General & Admin	26.42	24.61	22.83
Research & Development	83.5	73.95	88.19
Operating Expenses	109.91	98.55	111.03
Operating Income	57.59	-98.55	-111.03
Interest & Investment Income	4.65	1.97	2.03
Earnings From Equity Investments	-	-	-3.54
EBT Excluding Unusual Items	62.24	-96.59	-112.54
Gain (Loss) on Sale of Investments	-	-	-2.4
Other Unusual Items	-8.84	-3.83	-
Pretax Income	53.4	-100.42	-114.94
Income Tax Expense	1.17	-	-
Net Income	52.23	-100.42	-114.94
Preferred Dividends & Other Adjustments	48.83	-	-
Net Income to Common	3.41	-100.42	-114.94
Shares Outstanding (Basic)	2	2	2
Shares Outstanding (Diluted)	3	2	2
Shares Change (YoY)	19.33%	13.82%	-
EPS (Basic)	1.42	-43.89	-57.18
EPS (Diluted)	1.25	-43.89	-57.18
Free Cash Flow	74.81	-87.27	-101.17
Free Cash Flow Per Share	27.40	-38.14	-50.33
Gross Margin	100.00%	-	-
Operating Margin	34.38%	-	-
Profit Margin	2.03%	-	-
Free Cash Flow Margin	44.66%	-	-
EBITDA	60.88	-94.46	-107.21
EBITDA Margin	36.35%	-	-
D&A For EBITDA	3.3	4.09	3.82
EBIT	57.59	-98.55	-111.03
EBIT Margin	34.38%	-	-
Effective Tax Rate	2.20%	-	-

Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q